share_log

Expensify And 2 Other Stocks Under $2 Insiders Are Buying

Expensify And 2 Other Stocks Under $2 Insiders Are Buying

Expensify和其他2美元以下的股票內部人士正在買入
Benzinga ·  04/22 19:38

The Dow Jones index closed higher by over 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

道瓊斯指數週五收盤上漲超過200點。當內部人士購買或出售股票時，這表明他們對公司前景的信心或擔憂。對細價股感興趣的投資者和交易者可以將此視爲他們整體投資或交易決策的一個因素。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是細價股最近幾筆值得注意的內幕交易。欲了解更多信息，請訪問Benzinga的內幕交易平台。

BioCardia

BioCardia

  • The Trade: BioCardia, Inc (NASDAQ:BCDA) CEO and President Peter Altman acquired a total of 2,750 shares an average price of $0.37. To acquire these shares, it cost around $1,013.
  • What's Happening: On March 27, BioCardia posted a narrower-than-expected quarterly loss.
  • What BioCardia Does: BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs.
  • 交易：BioCardia, Inc（納斯達克股票代碼：BCDA）首席執行官兼總裁彼得·奧特曼共收購了2750股股票，平均價格爲0.37美元。收購這些股票的成本約爲1,013美元。
  • 發生了什麼：3月27日，BioCardia公佈的季度虧損低於預期。
  • BioCardia 做什麼：BioCardia Inc 是一家處於臨床階段的公司，開發細胞和細胞衍生療法，用於治療醫療需求未得到滿足的心血管和肺部疾病。

Expensify

昂貴化

  • The Trade: Expensify, Inc. (NASDAQ:EXFY) 10% owner SF Roofdeck GP LLC acquired a total of 143,639 shares at at an average price of $1.51. To acquire these shares, it cost around $216,222.
  • What's Happening: On Feb. 22, Expensify reported better-than-expected fourth-quarter adjusted EPS results.
  • What Expensify Does: Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money.
  • 交易：Expensify, Inc.（納斯達克股票代碼：EXFY）10％的所有者SF Roofdeck GP LLC共收購了143,639股股票，平均價格爲1.51美元。收購這些股票的成本約爲216,222美元。
  • 發生了什麼：2月22日，Expensify公佈的第四季度調整後每股收益好於預期。
  • Expensify的作用：Expensify Inc是一個基於雲的費用管理軟件平台，可幫助各種企業簡化資金管理方式。

Clearside Biomedical

克利爾賽德生物醫

  • The Trade: Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Anthony S Gibney acquired a total of 100,000 shares at an average price of $1.30. The insider spent around $129,665 to buy those shares.
  • What's Happening: On April 16, Clearside Biomedical named seasoned biotechnology executive Anthony S. Gibney to its Board of Directors.
  • What Clearside Biomedical Does: Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company.
  • 交易：Clearside Biomedical, Inc.（納斯達克股票代碼：CLSD）董事安東尼·吉布尼共收購了10萬股股票，平均價格爲1.30美元。知情人士花費了約129,665美元購買了這些股票。
  • 發生了什麼：4月16日，Clearside Biomedical任命了經驗豐富的生物技術高管安東尼·吉布尼爲董事會成員。
  • Clearside Biomedical的所作所爲：Clearside Biomedical Inc是一家總部位於美國的臨床生物製藥公司。

Read More: Albertsons Companies, Nucor And 3 Stocks To Watch Heading Into Monday

閱讀更多：週一艾伯森公司、紐柯和三隻股票值得關注

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論